CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

• ClinicalTrials.gov Identifier: NCT01773707
• Recruitment Status: Active, not recruiting
• First Posted: January 23, 2013
• Last Update Posted: April 15, 2022
• Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Collaborator: Juvenile Diabetes Research Foundation
• Information provided by (Responsible Party): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Description

Brief Summary:

The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial.

All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM.

The primary objective is to determine whether intervention with Abatacept will prevent or delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of patients with T1DM.

Secondary outcomes include: the effect of Abatacept on the incidence of T1DM; analyses of C-peptide and other measures from the OGTT; safety and tolerability; and mechanistic outcomes.

Condition or disease	Intervention/treatment	Phase
Abnormal Glucose Tolerance; Type 1 Diabetes	Drug: CTLA4-Ig (Abatacept); Drug: Placebo	Phase 2

Detailed Description:

Study Purpose and Rationale:

In this study, relatives who are confirmed to have two or more antibodies, not including mIAA, and normal glucose tolerance will be eligible for randomization to experimental treatment or placebo groups with the aim to determine whether experimental treatment will prevent or delay the occurrence of abnormal glucose tolerance and type 1 diabetes mellitus. Individuals with normal glucose tolerance are earlier in the disease process; that is, have less beta cell destruction than those with abnormal glucose tolerance or frank diabetes, yet will inevitably progress to clinical disease and essentially complete beta cell loss. Treatment at this early stage in a population who will inevitably progress to type 1 diabetes provides the greatest opportunity for a clinically important impact on disease prevention. With abnormal glucose tolerance rather than diabetes as the primary endpoint, study participants, regulators, funders, and investigators will be able to determine whether the therapy can alter disease progression.

Therefore, the rationale for this study is that individuals with immunologic markers of T1DM and normal glucose tolerance will inevitably develop clinical T1DM. Prior to development of clinical T1DM they will progress from normal glucose tolerance to abnormal glucose tolerance; and abnormal glucose tolerance results in clinical T1DM within 5 years in almost 80% of subjects. They have a condition that differs from overt diabetes only in the duration of the autoimmune process that results in beta cell destruction. Intervention early in the course of disease may be more effective than intervention in those with abnormal glucose tolerance or clinical T1DM.

Description of Treatment Groups

Subjects will be randomized to receive either Abatacept or placebo infusions along with close monitoring for abnormal glucose tolerance or diabetes. The infusions will be conducted at approved TrialNet clinical sites with appropriate facilities. All blood and serum samples for the primary and secondary outcome determinations will be sent to the Core Laboratories for analysis. Clinical laboratory studies may be done at the local sites.

Participants will be randomly assigned in a 1:1 ratio (within the two strata defined by age at enrollment: <18 and 18 or older) to the following 2 groups:

• to receive Abatacept (intravenous infusion at 0, 2, and 4 weeks following randomization, and then every 28+/-7 days) thereafter for a total of 14 doses. Close monitoring for diabetes development through the duration of study.
• to receive placebo intravenous infusion at 0, 2, and 4 weeks following randomization and then every 28+/- 7 days thereafter for a total of 14 doses. Close monitoring for diabetes development through the duration of study.

Treatment Assignment

After participants sign the consent form, complete the screening visit(s), and meet all of the inclusion criteria and none of the exclusion criteria, participants will be randomized to receive either Abatacept and close monitoring or placebo with close monitoring.

Participants will be randomized in equal allocations to each group. The randomization method will be stratified by TrialNet study site and whether the participant is less than 18 years of age or 18 years and older. This approach ensures that study site will not be a potential confounder. The TNCC will generate the randomization numbers and tables.

Study Assessments

During the course of the study, participants will frequently undergo assessments of their glucose tolerance status, insulin production, immunologic status, and overall health and well-being.

Samples will be drawn for storage in the National Institute for Diabetes and Digestive and Kidney Disease (NIDDK) Repository and at TrialNet Laboratory Sites for future analysis related to T1DM.

Study Duration

The study has been designed to provide 80% power to detect a 40% risk reduction in the occurrence of abnormal glucose tolerance using a two-sided test at the 0.05 level after six years of study duration. A total of approximately 206 patients will be allocated in a 1:1 ratio to the two groups.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 212 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Prevention
• Official Title: CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes
• Actual Study Start Date: March 2013
• Estimated Primary Completion Date: November 30, 2022
• Estimated Study Completion Date: November 30, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: abatacept IV infusion; CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)	Drug: CTLA4-Ig (Abatacept); Given as 30 minute IV infusion; Other Name: Abatacept
Placebo Comparator: Placebo; The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.	Drug: Placebo; Saline given as 30 minute IV infusion

Outcome Measures

Primary Outcome Measures :

1. Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance [ Time Frame: every six months for 5-6 years ]

   Measured by Oral Glucose Tolerance Test (OGTT):

   Abnormal Glucose Tolerance is primary endpoint and defined as:

   1. Fasting plasma glucose ≥ 110 mg/dL (6.1 mmol/L) and < 126 mg/dL (7 mmol/L), or
   2. 2 hour plasma glucose ≥ 140 mg/dL (7.8 mmol/L) and < 200 (11.1 mmol/L), or
   3. 30, 60, 90 minute plasma glucose during OGTT ≥ 200 mg/dL (11.1 mmol/L)

Secondary Outcome Measures :

1. Change in C-peptide response to Oral Glucose Tolerance Test (OGTT) [ Time Frame: Every six months for 5-6 years ]
   To Determine whether treatment with Abatacept is superior to placebo with respect to C-peptide response to oral glucose tolerance

Eligibility Criteria

• Ages Eligible for Study: 6 Years to 45 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Participant in TrialNet Natural History/Pathway to Prevention Study and thus, a relative of a proband with T1DM.
• Between the ages of 1-45 years at the time of enrollment in TN01 and age ≥ 6 at time of randomization in this trial.
• Willing to provide Informed Consent or have a parent or legal guardian provide informed consent if the subject is <18 years of age.

• Normal glucose tolerance by OGTT confirmed within 7 weeks (no more than 52 days) of baseline (visit 0). If previous abnormal glucose tolerance, has had two consecutive OGTTs with normal glucose tolerance.

  1. Fasting plasma glucose < 110 mg/dL (6.1 mmol/L), and
  2. 2 hour plasma glucose <140 mg/dL (7.8 mmol/L), and
  3. 30, 60, or 90 minute value on OGTT< 200mg/dL (11.1 mmol/L)
• At least two diabetes-related autoantibodies confirmed to be present on two occasions, not including mIAA. Confirmation of 2 positive autoantibodies must occur within the six months prior to randomization, but the confirmation does not have to involve the same 2 autoantibodies.
• Weight ≥ 20 kg at Baseline Visit.
• If a female participant with reproductive potential, willing to avoid pregnancy and undergo pregnancy testing prior to each infusion.
• At least three months from date of last live immunization.
• Willing to forgo live vaccines while receiving treatment on study and for three months following last study drug administration.

Exclusion Criteria:

• Abnormal Glucose Tolerance or Diabetes

  1. Fasting plasma glucose ≥ 110 mg/dL (6.1 mmol/L), or
  2. 2 hour plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or
  3. 30, 60, 90 minute plasma glucose during OGTT ≥ 200 mg/dL (11.1 mmol/L)
• Insulin autoantibodies (mIAA).
• Are immunodeficient or have clinically significant chronic lymphopenia.
• Have an active infection at time of randomization.
• Have a positive PPD test result or history of previously treated TB, or positive interferon-gamma release assay (IGRA) test.
• Be currently pregnant or lactating, or anticipate getting pregnant within 3 months of the last study drug administration.
• Use of medications known to influence glucose tolerance.
• Require use of other immunosuppressive agents.
• Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B core antibody or surface antigen), or Hepatitis C infection.
• Have serological evidence of current CMV infection.
• Have evidence of active EBV infection.
• Have any complicating medical issues or abnormal clinical laboratory results that interfere with study conduct or cause increased risk. These include pre-existing cardiac disease, COPD, neurological, or blood count abnormalities (such as lymphopenia, leukopenia, or thrombocytopenia).

Contacts and Locations

Locations

United States, California

University of California - San Francisco

San Francisco, California, United States, 94143

Stanford University Medical Center

Stanford, California, United States, 94305-5208

United States, Colorado

Barbara Davis Center for Childhood Diabetes, University of Colorado

Denver, Colorado, United States, 80262

United States, Connecticut

Yale Medical School

New Haven, Connecticut, United States

United States, Florida

University of Florida

Gainesville, Florida, United States, 32610-

University of Miami School of Medicine

Miami, Florida, United States, 33136

United States, Illinois

University of Chicago

Chicago, Illinois, United States, 60637

United States, Indiana

Indiana University-Riley Hospital for Children

Indianapolis, Indiana, United States, 46202

United States, Minnesota

University of Minnesota

Minneapolis, Minnesota, United States, 57931

United States, New York

Columbia University

New York, New York, United States

United States, Pennsylvania

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States, 15213

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213

United States, Tennessee

Vanderbilt University

Nashville, Tennessee, United States

United States, Texas

University of Texas Medical Center at Dallas

Dallas, Texas, United States, 75390-8858

Baylor College of Medicine

Houston, Texas, United States, 77030

United States, Washington

Benaroya Research Institute at Virginia Mason

Seattle, Washington, United States, 98101

Canada, Ontario

The Hospital for Sick Children

Toronto, Ontario, Canada, MSG-1X8

Sponsors and Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Juvenile Diabetes Research Foundation

Investigators

• Study Chair: Carla J Greenbaum, MD; Type 1 Diabetes TrialNet

More Information

Additional Information:

TrialNet 

Publications:

Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6. Epub 2011 Jun 28.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Leung SS, Borg DJ, McCarthy DA, Boursalian TE, Cracraft J, Zhuang A, Fotheringham AK, Flemming N, Watkins T, Miles JJ, Groop PH, Scheijen JL, Schalkwijk CG, Steptoe RJ, Radford KJ, Knip M, Forbes JM. Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells. Diabetes. 2022 Sep 1;71(9):1994-2008. doi: 10.2337/db22-0177.

• Responsible Party: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• ClinicalTrials.gov Identifier: NCT01773707
• Other Study ID Numbers: Abatacept (IND); UC4DK106993 ( U.S. NIH Grant/Contract ); UC4DK117009 ( U.S. NIH Grant/Contract )
• First Posted: January 23, 2013
• Last Update Posted: April 15, 2022
• Last Verified: April 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

prevention of type 1 diabetes; prevention of abnormal glucose tolerance

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intolerance; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Hyperglycemia; Abatacept; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents